This patient has been prescribed Soliris® (eculizumab) therapy, which increases the patient’s susceptibility to meningococcal infection (*Neisseria meningitides*) or other general infections.

- Meningococcal infections may become rapidly life-threatening or fatal if not recognized and treated early
- Evaluate immediately if infection is suspected and treat with appropriate antibiotics if necessary
- Contact prescribing physician (below) as soon as possible

For more information about Soliris, please refer to the full Prescribing Information. In case of safety concerns, call **1.888.SOLIRIS (1.888.765.4747)**. In case of adverse event experiences, call **1.844.259.6783**.

Patients receiving Soliris should carry this card at all times. Show this card to any doctor involved in your health care.

Patient Name __________________________________________

Prescriber Name ________________________________

Prescriber Number ______________________________

Soliris™ is a registered trademark of Alexion Pharmaceuticals, Inc. Copyright © 2018, Alexion Pharmaceuticals, Inc. All rights reserved. 1114.4.8.1.071

Reference ID: 4296864